CLONALX
DEAD

Serial Number

98550094

Owner

ACHILLES THERAPEUTICS UK LIMITED

Attorney

Rebecca Liebowitz

Filing Date

May 14, 2024

Add to watchlist:

No watchlists yet
View on USPTO

CLONALX Trademark

Serial Number: 98550094

CLONALX is a trademark filed by ACHILLES THERAPEUTICS UK LIMITED on May 14, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

ACHILLES THERAPEUTICS UK LIMITED (7 trademarks)

245 HAMMERSMITH ROAD
LONDON W6 8PW , GB

Entity Type: 24

Trademark Details

Filing Date

May 14, 2024

Registration Date

Not Registered

Goods & Services

Custom manufacture of therapeutic drugs, namely custom manufacture of cell therapies, cancer therapies, neoantigen-specific T cells, TCR-engineered T cells, cancer vaccines and neoantigen vaccines

Bioinformatics software; computer software platforms

Medical and veterinary preparations for therapeutic purposes; preparations for cancer therapy; antibodies; vaccines; personalised cancer vaccines; neoantigen vaccines; preparations for cell therapy; neoantigen-specific T cells; TCR-engineered T cells; preparations for modifying human or animal cells for medical or therapeutic purposes; preparations of blood extracted from humans or animals which have been adapted for medical or therapeutic purposes

Medical services; veterinary services; services in the extraction of human and animal cells from patients; manipulation of human and animal cells for therapeutic purposes; reinsertion of cells into human and animal patients; providing advice and consultancy in the field of medical and veterinary therapies; providing advice and consultancy in the field of cancer therapies and cancer vaccines

Scientific and technological services and research and design relating thereto; industrial analysis and research services; medical and veterinary research services including the manipulation of cells within a laboratory or research facility to enable the cells to be used for medical or therapeutic purposes; scientific research in the development of new cancer therapies, including neoantigen-specific T cells and TCR-engineered T cells; scientific research in human and animal cell therapy; scientific research into vaccines, including personalised cancer vaccines and neoantigen vaccines; scientific research into preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Apr 1, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Apr 1, 2025 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 5, 2024 GNRN
NON-FINAL ACTION E-MAILED
Dec 5, 2024 GNRT
NON-FINAL ACTION WRITTEN
Dec 5, 2024 CNRT
ASSIGNED TO EXAMINER
Nov 27, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 15, 2024 NWOS
NEW APPLICATION ENTERED
May 14, 2024 NWAP